An Open Label Trial Evaluating the Efficacy and Safety of Bruton's Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)
Latest Information Update: 27 May 2022
At a glance
- Drugs Zanubrutinib (Primary)
- Indications Neuromyelitis optica
- Focus Therapeutic Use
Most Recent Events
- 15 May 2022 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 15 May 2022 Status changed from not yet recruiting to recruiting.
- 06 May 2022 New trial record